Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD

Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD

Abstract Background Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (Ph-negative BCP-ALL) accounts for a significant portion of adult cases. Blinatumomab, a bispecific T-cell engager, has shown efficacy in relapsed or refractory BCP-ALL, but its role in induction therapy with re...

Full description

Bibliographic Details
Main Authors: Jing Lu, Yu Zhu, Huiying Qiu, Ying Wang, Xin Zhou, Haiping Dai, Xuzhang Lu, Bin Gu, Ming Hong, Miao Miao, Ruinan Lu, Jun Wang, Qian Wu, Mengxing Xue, Yun Wang, Ailing Deng, Yaoyao Shen, Yin Liu, Xueqing Dou, Yutian Lei, Xiaofei Yang, Suning Chen
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Discover Oncology
Subjects:
B-cell precursor acute lymphoblastic leukemia
Philadelphia chromosome-negative
Blinatumomab
Induction therapy
Online Access:https://doi.org/10.1007/s12672-025-01968-8

Internet

https://doi.org/10.1007/s12672-025-01968-8

Similar Items